inside the promptly evolving field of oncology investigate, precise and productive mutation screening is crucial for producing qualified therapies. The KRAS companies System plays a pivotal role in this landscape by providing comprehensive alternatives for KRAS mutation profiling and Evaluation. KRAS mutations, present in approximately ninety five%